We have investigated the frequency of p53 mutations in B-and T-cell human lymphoid malancies, including acute lymphoblastic leukemia, the major subtypes of non-Hodgkin lymphoma, and chronic lymphocytic leukemia. p53 exons 5-9 were studied by using genomic DNA from 197 primary tumors and 27 cell lines by single-strand conformation polymorphism analysis and by direct sequencing of PCRamplified fragments. Mutations were found associated with (i) Burkitt lymphoma (9/27 biopsies; 17/27 cell lines) and its leukemic counterpart L3-type B-cell acute lymphoblastic leukemia (5/9), both of which also carry activated c-myc oncogenes, and (ii) B-cell chronic lymphocytic leukemia (6/40) and, in particular, its stage of progression known as Richter's transformation (3/7). Mutations were not found at any significant frequency in other types of non-Hodgkin lymphoma or acute lymphoblastic leukemia. In many cases, only the mutated allele was detectable, implying loss of the normal allele. These results suggest that (i) signicant differences in the frequency of p53 mutations are present among subtypes of neoplasms derived from the same tissue; (ii) p53 may play a role in tumor progression in B-cell chronic lymphocytic leukemia; (ii) the presence of both p53 loss/inactivation and c-myc oncogene activation may be important in the pathogenesis of Burkitt lymphoma and its leukemic form L3-type B-cell acute lymphoblastic leukemia.
Burkitt lymphoma (9/27 biopsies; 17/27 cell lines) and its leukemic counterpart L3-type B-cell acute lymphoblastic leukemia (5/9), both of which also carry activated c-myc oncogenes, and (ii) B-cell chronic lymphocytic leukemia (6/40) and, in particular, its stage of progression known as Richter's transformation (3/7). Mutations were not found at any significant frequency in other types of non-Hodgkin lymphoma or acute lymphoblastic leukemia. In many cases, only the mutated allele was detectable, implying loss of the normal allele. These results suggest that (i) signicant differences in the frequency of p53 mutations are present among subtypes of neoplasms derived from the same tissue; (ii) p53 may play a role in tumor progression in B-cell chronic lymphocytic leukemia; (ii) the presence of both p53 loss/inactivation and c-myc oncogene activation may be important in the pathogenesis of Burkitt lymphoma and its leukemic form L3-type B-cell acute lymphoblastic leukemia.
Neoplasia involving the lymphoid system is characterized by marked biological and clinical heterogeneity including malignancies as distinct as acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL), and multiple myeloma. The pathogenesis of these malignancies is also heterogeneous, since distinct molecular lesions have been found associated with specific subtypes of lymphoid tumors (for review, see ref. 1). These lesions involve "dominantly acting" oncogenes activated either by chromosomal translocations, affecting c-myc in high-grade NHL and affecting bcl-2 in low-and intermediate-grade NHL, or by point mutations, affecting N-ras in ALL and multiple myeloma (1) . However, recent evidence has implied a role for "tumor suppressor genes" in tumorigenesis (reviewed in ref. 2) , the disruption or loss of which is thought to relieve the cell from negative regulatory signals. While various studies (3) (4) (5) (6) have shown that tumor suppressor genes-namely, Rb and p53-are the site of frequent lesions in multiple types of human tumors, their involvement in human lymphoid malignancies has not been comprehensively investigated.
The p53 gene (7) encodes a 53-kDa nuclear phosphoprotein that may be involved in the negative regulation of cell growth. Several lines of evidence support the notion that its loss or alteration may contribute to the deregulated growth characteristics of cancer cells. First, several types of human tumors display the monoallelic loss of variable portions of the short arm of chromosome 17 (5) . In the case of colon cancer, it has been shown that the region 17p13.1, the site of the p53 locus (8) , is consistently lost (4) . Second, consistent with Knudson's model of tumor suppressor genes (9), it was found that the 17p13.1 loss was consistently associated with mutations of the residual p53 allele, which are thought to inactivate the remaining p53 function (4-6). Finally, functional evidence for the tumor suppressor role of p53 was achieved by showing that normal p53 can inhibit the transformation of rodent cells and can revert the malignant phenotype of human carcinoma cells in vitro (10) (11) (12) . However, p53 may differ in some respects from the prototype of tumor suppressor genes, in that at least some p53 mutant alleles can behave as dominant oncogenes by transforming target cells in vitro and causing tumorigenesis in transgenic mice even in the presence of the normal allele (13, 14) . Regardless of the exact mechanism involved, p53 mutations and allelic losses can now be considered as a relatively frequent pathogenetic feature of several types of human malignancies, including those of the colon, breast, lung, brain, and soft tissues (refs. [4] [5] [6] ; for review, see ref. 15) .
Several lines of indirect evidence suggest that alterations of the p53 gene might be relevant to the development of lymphoid neoplasia in humans, including the development of lymphomas in transgenic mice carrying mutant p53 alleles (14) , the presence of high levels of p53 expression, typical of tumors harboring p53 mutations, in lymphoproliferative disorders (16) , and the presence of p53 mutations in a few T-ALL cell lines tested (17 Oligonucleotide Primers. All of the oligonucleotides used for PCR amplification in this study were synthesized by the solid-phase triester method (22) . Names and sequences ofp53 primers derived from published sequences (23) Single-Strand Conformation Polymorphism (SSCP) Analysis. SSCP analysis was accomplished according to an adapted version of a previously reported method (24) . Briefly, PCRs were performed with 100 ng of genomic DNA, 10 pmol of each primer, 2.5 ,uM dNTPs, 1 ,Ci of [a-32P]dCTP (NEN; specific activity, 3000 Ci/mmol; 1 Ci = 37 GBq), 10 mM Tris HCI (pH 8.8), 50 mM KCI, 1 mM MgCl2, 0.01% gelatin, 0.5 unit of Taq polymerase (Cetus), in a final vol of 10 ,ud. Thirty cycles of denaturation (94°C), annealing (63°C for reactions amplifying exons 5, 6, 7, and 9; 58°C for exon 8), and extension (72°C) were done on an automated heat-block (DNA thermal cycler; Perkin-Elmer/Cetus). The reaction mixture (2 ul) was diluted 1:25 in 0.1% NaDodSO4/10 mM EDTA and further mixed 1:1 with a sequencing stop solution (19) containing 20 mM NaOH. Samples were heated at 95°C for S min, chilled on ice, and immediately loaded (3 ,ul) onto a 6% acrylamide/TBE gel containing 10% (vol/vol) glycerol.
Gels were run at 8 W for 12-15 h at room temperature. Autoradiography was performed with an intensifying screen for 6-72 h.
Direct Sequencing of PCR Products. PCR was performed with 500 ng ofgenomic DNA, 20 pmol ofeach primer, 200,uM dNTPs, 10 mM Tris-HCl (pH 8.8), 50 mM KCl, 1 mM MgCl2, 0.01% gelatin, and 2.5 units of Taq polymerase. The number and conditions of amplification cycles were as described above. Direct sequencing of the amplified product was performed as described (25) .
RESULTS
Experimental Plan. We selected 197 cases, representative of the spectrum of human lymphoid malignancies (Table 1) , from our collection of pathologic specimens based on un- examined by direct sequencing of the PCR-amplified exons (see Table 2 for summary and Fig. 2 Table 2 ).
The location of mutations affecting the p53 gene has been reported to correspond to regions of the gene displaying high homology among different species (26) . Thirty-five point mutations fell into these regions or their immediate boundaries, while 12 were located at other sites, mainly between codons 205 and 216.
To confirm the assumption that p53 mutations in BL represent a somatic event, we analyzed the DNA from three lymphoblastoid cell lines and one T-cell clone obtained from four corresponding BL patients that had been shown to harbor p53 mutations. In each case, the mutation was detected only in the tumor tissue, thus suggesting that it had arisen during the neoplastic process (Fig. 1) .
In 24 cases (marked with asterisk in Table 2 ; 13/27 mutated biopsies; 11/17 mutated cell lines), the wild-type sequence at the mutation site was either not detectable or was present at low intensity, presumably reflecting the loss of the normal allele ( Fig. 2; see below) . In two BL primary tumors (HO4024 and H03876) and two BL cell lines (P3HR1 and BL49), two mutations were observed at different codons, all in the presence of the wild-type band (Fig. 2) ; in two other cases (Ramos and Namalwa), one codon displayed two mutations. Whether these mutations reside on the same allele or on different chromosomes has not been assessed.
Finally, it is noteworthy that almost one-third (4/13) of cases displaying an abnormal SSCP migration pattern for exon 6 (i.e., 1.78% of all cases analyzed) contained a silent mutation at codon 213 when assayed by direct sequencing, suggesting the presence of a polymorphism.
DISCUSSION
Our data indicate that point mutations in the p53 gene do not represent a general lesion in lymphoid neoplasia but, rather, are specifically associated with certain subtypes of malignancies such as BL and B-CLL. Previously available data were limited to the analysis of a few T-ALL cell lines (17) in which mutations were detectable at a relatively high frequency. This observation, however, was not confirmed by our analysis of primary T-ALL samples. There may be multiple reasons for this discrepancy, but a higher frequency of mutations in cell lines versus primary samples is also observed in this study for BL (63% vs. 33%). While it remains possible that p53 mutations and deletions may frequently occur during in vitro establishment or culture (10, 27) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . (4) (5) (6) 15) ; among the remaining 11 mutations, 8 involve highly conserved domains of the p53 protein (26) . Second, the vast majority of predicted p53 amino acid substitutions in lymphoid malignancies involve regions of the protein that are highly conserved through evolution (26) and/or correspond to regions of the mouse p53 gene whose mutations result in its oncogenic activation (10) . Finally, the recent evidence (29) of germ-line p53 mutations may raise the issue of the germline versus somatic nature of the observed mutations. For four cases, the absence of mutations in non-tumor DNA could be demonstrated. In addition, no evidence of familiar predisposition has been reported for most lymphoid malignancies (30) , suggesting that the observed p53 mutations represent somatic events occurring during tumorigenesis.
The results presented here have implications for the role of p53 as either a recessive or a dominant-negative oncogene. In a sizable proportion of cases only the mutated p53 allele was found, while the normal allele has presumably been lost.
Although deletions of the short arm of chromosome 17 have been described in lymphomas (31), BL and B-CLL in particular are not frequently associated with cytogenetic alterations of region 17p (32, 33) ; we conclude that, in these two types of lymphoid malignancies, the loss of the normal p53 allele may reflect cytogenetically undetectable events such as small deletions within the 17p13 region or the loss of one chromosome and the duplication of the remaining mutated chromosome. In all these cases, however, it appears that mutated p53 alleles act as typical recessive oncogenes. Conversely, the interpretation of those cases in which both a normal and a mutated p53 allele are detectable is more difficult. In these cases we could not distinguish whether this finding reflects: (i) hemizygosity for the mutated allele, the normal one being present only in contaminating normal cells; or (ii) true p53 heterozygosity of the tumor cells, with the mutated allele acting as a dominant-negative oncogene; or (iii) "first step" p53 heterozygosity (possibly with no phenotypic effect), which may be followed by "second step" loss of the normal allele, allowing for the recessively acting action of the mutated allele. Further studies combining the analysis of p53 mutation and loss of heterozygosity along the 17p region in sequential tumor samples may help in addressing these issues.
The association between B-CLL and p53 mutation occurs at low frequency, yet it is noteworthy in view of the paucity of information regarding the involvement of either dominant or recessive oncogenes in this malignancy. On the other hand, a number of cytogenetic abnormalities, presumably reflecting unknown oncogene activation events, have been identified and shown to have prognostic significance in this disease (33) . It may be interesting to note that, within the general B-CLL category, p53 mutations appear to be more frequent in Richter's syndrome, which represents the evolution of B-CLL into a highly aggressive malignancy. Further studies based on a larger number of cases will clarify whether Proc. Natl. Acad Sci. USA 88 (1991) p53 mutations significantly correlate with B-CLL neoplastic progression. Among all types of lymphoid neoplasia, the most frequent targets for p53 mutations are BL and L3-type B-ALL. BL includes two pathogenetically distinct forms-namely, the endemic African type characterized in virtually all cases by Epstein-Barr virus infection and the sporadic American type characterized by Epstein-Barr virus infection in only 309o of cases. The L3-type B-ALL leukemic cells are morphologically similar to BL, suggesting that this tumor is a leukemic manifestation of BL. A common denominator among all these diseases is the consistent presence of chromosomal translocations leading to c-myc oncogene activation (reviewed in ref. 1). Interestingly, p53 mutations have also been found at high frequency in those cases of AIDS-associated lymphoma that carry an activated c-myc oncogene (P.B., G.G., G.I., J.Z.G., G. Saglio, D.M.K., and R.D.-F., unpublished data). Whether p53 mutation/loss and c-myc activation by chromosomal translocation act synergistically in the pathogenesis of the Burkitt type phenotype remains to be determined.
